The Wide Price Range of a Single Cancer Drug
Hospitals in the US are significantly marking up the prices of old, generic cancer drugs, sometimes by hundreds of times the Medicare rate, leading to inflated costs for patients and insurers. This practice, driven by hospital profit motives and opaque pricing systems, results in substantial financial burdens on patients and health plans, despite the drugs being inexpensive to produce. Efforts to increase price transparency and regulate these markups are ongoing, but the problem remains complex and widespread.
